CHARLOTTESVILLE, Va., Sept. 23, 2021 /PRNewswire/ -- BrightSpec, Inc. announced today the appointment of R. Terry Dunlay to the Board of Directors, effective as of September 1, 2021.
Mr. Dunlay brings more than 30 years of life science industry experience. Terry was the founder and CEO of IntelliCyt Corporation which developed instrumentation, software, and reagents for immunology and immuno-oncology applications. IntelliCyt was acquired by Sartorius AG of Germany in 2016. Prior to founding IntelliCyt, Terry was co-founder of Cellomics, a Pittsburgh, PA based automated cellular analysis company that was acquired by Thermo Fisher in 2005. Subsequent to his operating roles, Mr. Dunlay has remained active in the life science industry through directorships (Mindset Integrated, Wavefront Dynamics, and BennuBio) and non-profit participation (Lovelace Biomedical Research Institute). He holds an MS and BS in Electrical Engineering.
"We are pleased to announce the appointment of Terry to our board of directors," said Walter Colsman, Chief Executive Officer of BrightSpec. "Terry brings a wealth of expertise gained over his entrepreneurial career in the life sciences. This timely addition to the board comes as we are accelerating our commercialization efforts. Terry's track record of developing successful companies that are subsequently acquired will certainly bring value to both our current and future investors."
"BrightSpec's MRR instruments offer a highly differentiated approach to molecular analysis. With multiple high-value applications, there is great potential for growth across multiple market segments. I am excited to join the Board to offer the benefit of my experience scaling these types of businesses," said Mr. Dunlay.
To learn more about BrightSpec and the spectraMRR platform, please visit www.brightspec.com.
About BrightSpec
BrightSpec is the leading life science tools company commercializing instruments that harness the power of molecular rotational resonance (MRR) spectroscopy. MRR is an innovative approach to rapidly and definitively characterize the unique three-dimensional structure of small molecules, including all forms of structural and spatial isomers. BrightSpec offers a vertically integrated platform that includes quantum simulation, rotational spectrometers, data analysis tools, and automation with the goal of bringing this technology to the forefront of the applied sciences, including the pharmaceutical, chemical, and consumer goods industries.